CBG002 CAR-T cell therapy for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy called CAR-T that targets a protein called BCMA on myeloma cells. It is for people whose myeloma has come back or not responded to at least three prior treatments, and who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old.
- You have multiple myeloma that has returned or not responded after at least three different treatments.
- Your myeloma can be measured (for example, by blood tests or scans).
- You have not had a stem cell transplant from someone else, and if you had your own stem cells infused, that was more than 12 weeks ago.
- Your organs (heart, kidneys, liver, etc.) are working well enough, and you are in generally stable health.
- You have not had a prior CAR-T treatment or any therapy that targets BCMA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.